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Original Article

A Humoral Immune Response Alters the
Distribution of Enzyme Replacement Therapy
in Murine Mucopolysaccharidosis Type I
Steven Q. Le,1,3 Shih-hsin Kan,1,3 Don Clarke,1 Valentina Sanghez,1 Martin Egeland,1 Kristen N. Vondrak,1
Terence M. Doherty,1 Moin U. Vera,1 Michelina Iacovino,1 Jonathan D. Cooper,1 Mark S. Sands,2
and Patricia I. Dickson1
1Los

Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA; 2Department of Medicine, Washington University School of

Medicine in St. Louis, St. Louis, MO 63110, USA

Antibodies against recombinant proteins can signiﬁcantly
reduce their effectiveness in unanticipated ways. We evaluated
the humoral response of mice with the lysosomal storage disease
mucopolysaccharidosis type I treated with weekly intravenous
recombinant human alpha-L-iduronidase (rhIDU). Unlike patients, the majority of whom develop antibodies to recombinant
human alpha-L-iduronidase, only approximately half of the
treated mice developed antibodies against recombinant human
alpha-L-iduronidase and levels were low. Serum from antibodypositive mice inhibited uptake of recombinant human alpha-Liduronidase into human ﬁbroblasts by partial inhibition
compared to control serum. Tissue and cellular distributions
of rhIDU were altered in antibody-positive mice compared to
either antibody-negative or naive mice, with signiﬁcantly less
recombinant human alpha-L-iduronidase activity in the heart
and kidney in antibody-positive mice. In the liver, recombinant
human alpha-L-iduronidase was preferentially found in sinusoidal cells rather than in hepatocytes in antibody-positive mice.
Antibodies against recombinant human alpha-L-iduronidase
enhanced uptake of recombinant human alpha-L-iduronidase
into macrophages obtained from MPS I mice. Collectively, these
results imply that a humoral immune response against a therapeutic protein can shift its distribution preferentially into
macrophage-lineage cells, causing decreased availability of the
protein to the cells that are its therapeutic targets.

both a reduced effectiveness of treatment and a signiﬁcant humoral
immune response.3
The humoral immune response to recombinant protein therapies for
lysosomal storage diseases can reduce the efﬁcacy of treatment either
by neutralizing enzymatic activity directly, presumably by interfering
with the enzyme’s active site, or by interfering with binding the
mannose 6-phosphate receptor, thus blocking cellular uptake and
lysosomal targeting.4 Using the naturally occurring canine model of
MPS I, we reported that serum from dogs with a humoral immune
response against rhIDU diminished its intracellular uptake into
MPS I patient ﬁbroblasts in vitro, suggesting that antibodies may
reduce the effectiveness of rhIDU by limiting its uptake into cells.5
Antibodies against rhIDU also altered the distribution of rhIDU
in vivo as well. rhIDU preferentially localized to tissues, such as
lymph nodes, liver, and spleen, that had greater reticuloendothelial
content, and correspondingly less rhIDU distributed to other organs,
such as myocardium, lung, and renal medulla.5 In MPS I, heart valves
and synovium are particularly difﬁcult to treat, and we found that abnormalities in these tissues did not improve following rhIDU treatment in MPS I dogs with high antibody titers. However, heart valves
and synovium from low-titer dogs treated with high-dose intravenous
rhIDU appeared morphologically normal.5 These results suggest that
enzyme replacement therapy is incompletely effective in patients who
develop antibodies against rhIDU because these antibodies divert
rhIDU away from tissues that need it most.

INTRODUCTION
Recombinant proteins are used clinically to treat dozens of conditions
typically caused by a genetic lack of the protein, for example, clotting
factor deﬁciencies and lysosomal storage diseases. If these recombinant proteins are sensed as foreign, humoral immune responses
that signiﬁcantly limit effectiveness can develop. For example,
patients with infantile Pompe disease who develop neutralizing antibodies against recombinant human acid alpha-glucosidase can deteriorate and die because the recombinant enzyme is less effective and is
unable to prevent disease progression.1,2 In MPS I, antibodies against
recombinant human alpha-L-iduronidase (rhIDU) are associated
with reduced clearance of glycosaminoglycans from urine, indicating
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One mechanism that could explain the altered distribution of rhIDU
that we observed in MPS I dogs is that antibody-bound rhIDU is taken
up by reticuloendothelial cells, perhaps via Fc receptors. Uptake of
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rhIDU normally occurs via the mannose 6-phosphate receptor, and our
previous results suggest that antibodies against rhIDU interfere with
this receptor-mediated uptake pathway.5 Hence, excess rhIDU might
be more likely to be removed from circulation by reticuloendothelial
cells. Supporting this notion are data demonstrating that when mannose
6-phosphates are absent from recombinant beta-glucuronidase, which
is then administered intravenously to MPS type VII mice, tissue distribution in the liver showed predominant uptake by Kupffer cells rather
than hepatocytes, but the intact enzyme was evenly distributed to both
cell types.6 The ﬁndings from these previous studies suggest that uptake
via the mannose 6-phosphate receptor is necessary for even distribution
of recombinant lysosomal enzymes to parenchymal tissues.

weekly with rhIDU and developed a humoral immune response. We
then imaged the mice in vivo and ex vivo using ﬂuorescent imaging
(Figure 1). We compared six naive with ﬁve antibody-positive MPS
I mice and found that antibody-positive MPS I mice had lower
ﬂuorescence intensity than naive MPS I mice in all organs by approximately 33%–70% (Figure 1C). Intergroup differences between antibody-positive and naive mice reached statistical signiﬁcance for the
heart (t(7.31) = 3.44; p = 0.010) by a two-sample t test, separate variances. Two of the antibody-positive mice showed zero ﬂuorescence
intensity in the lung, kidney, and/or heart, which are organs with relatively low reticuloendothelial content (Figure S3).
rhIDU Enzymatic Activity Was Significantly Reduced in HighTiter MPS I Mice

RESULTS
Modest Humoral Immune Response to rhIDU in MPS I Mice

There were three groups of experimental mice. One “naive” group of
MPS I mice (n = 6) received a single 1.57 mg/kg dose of ﬂuorescentlabeled rhIDU at 16 weeks of age. These mice were considered naive
because they lacked prior exposure to rhIDU and therefore would
not mount a humoral immune response when a single dose of ﬂuorescent-labeled rhIDU was administered. Thirteen MPS I mice received
weekly tail vein injections of 1.57 mg/kg rhIDU from 4 to 15 weeks
of age, followed by treatment with a single dose of ﬂuorescent-labeled
rhIDU at 16 weeks of age. In prior canine studies, intravenous rhIDU
administration to MPS I dogs resulted in a humoral immune response
in all immune-competent animals. Anti-rhIDU gamma-immunoglobulin (IgG) antibody titers ranged from 16 to 678 optical density (OD)
U/mL in dogs that did not receive immune tolerization.7 However, in
the present experiment, only eight mice receiving rhIDU developed
an anti-rhIDU IgG antibody titer, and these titers ranged from 3 to
30 OD U/mL. We designated these mice as “antibody positive.” Two
of these mice died 1 hr after an infusion from presumed infusion reactions and one was found dead 3 days post-infusion. Five MPS I mice
receiving rhIDU had titers <1 OD U/mL that were considered negligible. These mice were designated “antibody negative” (Figure S1).
Serum from 12 untreated MPS I mice and 10 normal mice were evaluated for anti-rhIDU antibodies as controls. Titers in the 12 naive
MPS I mice ranged from 0 to 0.108 OD U/mL undiluted serum (average
0.032 ± 0.040 OD U/mL), and for 10 naive normal mice, titers ranged
from 0.001 to 0.577 (average 0.086 ± 0.178) OD U/mL undiluted serum.
It is not clear why some mice mounted an immune response and some
did not. However, the mice that failed to mount an immune response to
rhIDU provided the opportunity to compare rhIDU distribution in
naive mice with mice that mounted a humoral immune response
and mice that mounted a negligible humoral immune response. We
conﬁrmed that the humoral immune response to rhIDU in antibody-positive MPS I mice partially inhibited uptake of rhIDU into
MPS I human ﬁbroblasts using an in vitro uptake assay (Figure S2).
Uptake of rhIDU in Liver and Heart Was Significantly Reduced in
High-Titer MPS I Mice

To study the effect of anti-rhIDU antibodies on rhIDU distribution,
we administered ﬂuorescent-labeled rhIDU intravenously to adult
MPS I mice that were either naive to rhIDU or that had been treated

To determine whether there were differences in enzymatic activity of
rhIDU as a function of altered biodistribution, we assayed rhIDU enzymatic activity in antibody-negative and antibody-positive mice. Because
naive MPS I mice received a single rhIDU dose rather than 16 weekly
rhIDU doses, the enzymatic activity of their tissues was not expected
to be comparable, and thus the naive mice were not included in studies
of rhIDU activity. rhIDU enzymatic activities were generally consistent
with ex vivo ﬂuorescence imaging results (Figure 1D). Antibody-positive MPS I mice had 2.4-fold lower rhIDU activity in the kidney
(t(4.50) = 2.67; p = 0.049) and 3.7-fold lower rhIDU activity in the
heart (t(4.14) = 2.80; p = 0.047) compared to antibody-negative
mice (two-sample t test, separate variances). There were no noticeable
differences in liver, lung, or spleen rhIDU activity between the antibody-positive and antibody-negative MPS I mice treated with rhIDU.
Fluorescence Labeling Did Not Affect Enzymatic Activity of
rhIDU

To exclude the possibility that enzymatic activities of rhIDU and ﬂuorescent-labeled rhIDU systematically differed, we compared rhIDU
enzymatic activity (measured by biochemical assay) with ﬂuorescence
intensity ex vivo in organs of antibody-negative and antibody-positive
mice. Linear regression showed a relationship between ex vivo ﬂuorescence intensity measurements of whole organs and alpha-L-iduronidase (IDU) activity in homogenized tissue in the heart and
lung (heart: r2 = 0.86, F(1,8) = 47.94, p < 0.001; lung: r2 = 0.49,
F(1,8) = 7.67, p = 0.02; Figure S3). There were no signiﬁcant mean
intergroup differences between ﬂuorescence intensity measurements
of ﬂuorescent-labeled rhIDU versus those that we found using rhIDU
activity by enzymatic assay (p = non-signiﬁcant [NS]). There was less
agreement in the kidney, where the difference that we measured
between antibody-negative and antibody-positive groups using
ex vivo ﬂuorescence (0.75 ± 0.56) was smaller than the difference
that we measured using the rhIDU activity assay (1.44 ± 1.17;
p = NS). The reason for the slight but statistically insigniﬁcant
disparity may be that the presence of dissociated ﬂuorescent label
in the urine was causing a high ﬂuorescence signal in both the antibody-negative and antibody-positive humoral immune response
groups, thus diluting the intergroup difference that we observed. To
test this hypothesis, we evaluated the bladders and urine of treated
mice. Mice that were treated with ﬂuorescent-labeled rhIDU showed
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Figure 1. Distribution of Fluorescent-Labeled rhIDU
Distribution of rhIDU labeled with Alexa Fluor 680 (rhIDU-AF680) in naive, antibody-negative (anti-rhIDU IgG antibody < 1 OD U/mL), and antibody-positive (anti-rhIDU IgG
antibody > 3 OD U/mL) MPS I mice. (A) False color ex vivo imaging of internal organs from a representative mouse from two untreated MPS I mice (MPS I No Tx; top row) and a
representative mouse from six rhIDU-AF680-treated MPS I mice (AF680; bottom row) 24 hr after injection of labeled enzyme. Autofluorescence was apparent in some tissues
(arrows). (B) Fluorescence intensity in vivo in the whole mouse. Naive MPS I mice (i.e., mice that had no previous rhIDU exposure; filled circles; n = 6) are compared to
untreated MPS I control mice (open circles; n = 2). (C) Distribution of rhIDU to internal organs ex vivo in six naive MPS I mice (Naive), six antibody-negative MPS I mice
(AB Neg), five antibody-positive MPS I mice (AB Pos), and two untreated MPS I mice (MPS I NoTx). Average fluorescence intensity was measured 24 hr after injection of
rhIDU-AF680. Signals in untreated MPS I mice (MPS I No Tx) represent autofluorescence. (D) IDU enzymatic activity in internal organs of antibody-positive- and antibodynegative-treated MPS I mice (n = 5 per group) after 16 weeks of rhIDU treatment compared to untreated MPS I control mice (n = 10). Untreated normal control mice (we used
wild-type littermates) received no treatment (n = 10; Normal No Tx). Error bars represent SD. *p < 0.05.

a bright ﬂuorescence signal in the bladder, but their urine contained
no measurable rhIDU activity, suggesting that the ﬂuorescence intensity that we observed in the bladder was due to free ﬂuorescent label
that had been excreted into the urine (Figure S4).
Altered Cellular Distribution of rhIDU in the Liver of AntibodyNegative and Antibody-Positive Mice

Ex vivo imaging of the whole liver revealed that antibody-negative
MPS I mice had similar overall ﬂuorescence intensity as antibody-
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positive MPS I mice, whereas in other organs, the antibody-negative
MPS I mice appeared similar to naive mice, with respect to accumulation of labeled enzyme (Figure 1C). The liver is relatively rich in
macrophage-lineage cells, such as sinusoidal Kupffer cells, that may
be expected to take up rhIDU even when it is bound to antibodies.
We therefore hypothesized that rhIDU might be preferentially localized to sinusoidal cells rather than hepatocytes within the livers of
high-titer mice, whereas low-titer mice may show a more even distribution of rhIDU between sinusoidal cells and hepatocytes. To test this
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Figure 2. Altered Cellular Distribution of rhIDU in High-Titer Mice Compared to Low-Titer Mice
Immunohistochemistry of liver tissue sections using anti-rhIDU antibody (1:2,000, brown). Representative images are shown of untreated wild-type mice (Normal NoTx;
n = 4), untreated MPS I mice (MPS I NoTx; n = 3), MPS I mice treated with rhIDU with anti-IDU antibody titers 3–30 OD U/mL (AB Positive; n = 5), and MPS I mice treated with
rhIDU with anti-IDU antibody titers < 1 OD U/mL (AB Negative; n = 5). Liver sinusoidal cells are indicated by arrowheads. Top row: 20 magnification. Bottom row:
63 magnification. Scale bar, 50 mm.

hypothesis, antibody-negative mice and antibody-positive mice
were compared using immunohistochemistry to determine whether
the humoral immune response alters the cellular distribution of
rhIDU (Figures 2 and S5). In the liver, rhIDU was found in sinusoidal
cells that morphologically appeared to be Kupffer cells in both antibody-negative and antibody-positive MPS I mice. However, antibody-positive MPS I mice showed qualitatively less rhIDU in
hepatocytes.
With the observed differences in rhIDU distribution between antibody-negative and antibody-positive mice, we reasoned that the
lysosomal accumulation of dermatan and heparan sulfate glycosaminoglycans (the substrates for IDU) would be reduced in
low-titer mice compared to high-titer mice in organs. Glycosaminoglycan levels were lower in antibody-positive-treated MPS I mice,
antibody-negative-treated MPS I mice, and untreated control mice
compared to untreated MPS I mice in the liver (F(3,26) = 14.61;
p % 0.001 by ANOVA with post hoc Dunnett’s test), spleen
(F(3,16) = 36.79; p < 0.001 by ANOVA with post hoc Dunnett’s
test), and kidney (F(3,26) = 9.70; p % 0.001 by ANOVA with
post hoc Dunnett’s test). For the lung, a statistically signiﬁcant difference in glycosaminoglycan levels compared to untreated MPS I
mice was found only for control and antibody-positive-treated
MPS I mice (F(3,16) = 4.49; p = 0.01 by ANOVA with post hoc
Dunnett’s test), and for the heart, signiﬁcance was found only for
antibody-positive- and antibody-negative-treated MPS I mice
(F(3,26) = 5.90; p % 0.007 by ANOVA with post hoc Dunnett’s
test). We found no difference in glycosaminoglycan values by
biochemical assay of whole organ homogenates between antibodypositive and antibody-negative MPS I mice treated with rhIDU
(Figure 3A). However, at the tissue level, we found a qualitatively
greater reduction in liver staining for lysosomal associated
membrane protein-1 (Lamp1) (a marker of lysosomal storage) in

antibody-negative MPS I mice compared with antibody-positive
MPS I mice treated with rhIDU (Figures 3B and 3C), indicating
that anti-rhIDU antibodies may be adversely affecting the ability
of rhIDU to reduce lysosomal storage in the liver.
Enhanced rhIDU Uptake into Macrophages in the Presence of
Anti-rhIDU Antibodies

Because rhIDU preferentially localized to sinusoidal cells in antibodypositive mice, we performed an in vitro experiment to determine
whether macrophages, which express Fc receptors as well as mannose
6-phosphate receptors, could take up rhIDU in the presence of antirhIDU antibodies. We isolated macrophages from bone marrow
obtained from MPS I mice and incubated these bone-marrow-derived
macrophages with rhIDU in the presence or absence of immunized
rabbit serum, a murine Fc receptor blocking agent, and/or mannose
6-phosphate. We evaluated two types of immunized rabbit serum:
one that completely abolished rhIDU uptake into human MPS I ﬁbroblasts (inhibiting serum [IS]) and one that only partially inhibited
rhIDU uptake into ﬁbroblasts (partially inhibiting serum [PIS]). In
the absence of immune serum, uptake of rhIDU into ﬁbroblasts
was not signiﬁcantly different from uptake into murine macrophages
(Figure 4A; t(4.59) = 2.54; Bonferroni-adjusted p = 0.54). In
the presence of immune serum, uptake of rhIDU into macrophages
per cell was greater than uptake into ﬁbroblasts (Figure 4B;
t(5.00) = 4.04; Bonferroni-adjusted p = 0.089; and Figure 4C,
t(4.57) = 5.53; Bonferroni-adjusted p = 0.04). The uptake of rhIDU
into murine macrophages in the presence of immune serum
(17.2–118 activity units per 106 cells) was also greater than uptake
into murine macrophages in the absence of serum (1.07–18.2 U per
106 cells). The uptake of rhIDU into murine macrophages was only
partially inhibited by mannose 6-phosphate, whereas uptake of
rhIDU into human ﬁbroblasts was nearly abolished with the addition
of mannose 6-phosphate, consistent with prior results.8 Murine Fc
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Figure 3. Lysosomal Storage in MPS I Mice
(A) Glycosaminoglycan levels in internal organs of antibody-positive and antibody-negative MPS I mice (n = 5 per group) after 16 weeks of rhIDU treatment compared to
controls. Ten untreated MPS I mice (MPS I NoTx) and ten untreated wild-type normal mice (Normal NoTx) were used as controls (n = 10 per group). Glycosaminoglycans were
measured by the carbazole reaction and reported as mol glucuronic acid (GA) per mg protein. Error bars represent SD. *p < 0.05 versus MPS I NoTx. (B and C) Lysosomalassociated membrane protein staining in liver of MPS I and normal mice. Representative images are shown of untreated wild-type mice (Normal NoTx; n = 3), untreated MPS I
mice (MPS I NoTx; n = 3), MPS I mice treated with rhIDU with anti-IDU antibody titers 3–30 OD U/mL (AB Positive; n = 4), and MPS I mice treated with rhIDU with anti-IDU
antibody titers < 1 OD U/mL (AB Negative; n = 4). 20 magnification (B); scale bar, 100 mm (B). 40 magnification (C); scale bar, 50 mm.

receptor blocking agent did not substantially affect the uptake of
rhIDU into either murine macrophages or human ﬁbroblasts. However, the blocking agents do not bind to all Fc receptors, limiting
our ability to draw conclusions about the mechanism of antibodybound rhIDU uptake into macrophages.
To conﬁrm that the enhanced macrophage uptake that we observed in
the presence of immune serum was due to anti-rhIDU antibodies
within the serum, we puriﬁed rabbit anti-rhIDU IgG antibodies
from serum and applied them to murine MPS I macrophages in the
presence of rhIDU. We found a mean 16-fold increase in rhIDU
uptake into murine MPS I macrophages in the presence of the
puriﬁed anti-rhIDU IgG antibodies compared with no antibodies
(F(6, 35) = 5.00; p = 0.001; Figure 4D). This result suggests that
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anti-rhIDU IgG antibodies were the cause of the increased rhIDU
uptake into macrophages that we observed in the presence of immune
serum.

DISCUSSION
Here, we report the maldistribution of rhIDU with low levels of antiiduronidase antibodies in MPS I mice receiving intravenous rhIDU.
The study demonstrated that even a low-level humoral immune
response against rhIDU, which only partially inhibits rhIDU uptake
into ﬁbroblasts in vitro, nevertheless altered its tissue distribution
in vivo. At the cellular level, antibody-positive mice showed reduced
rhIDU distribution in hepatocytes, whereas distribution to tissue
macrophages was maintained. In vitro, immunized serum reduced
rhIDU uptake into human ﬁbroblasts, but increased uptake into
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Figure 4. Uptake of rhIDU into MPS I Human Fibroblasts and Murine Macrophages
(A–C) Intracellular IDU activity per million cells in the absence of immune serum (A), in the presence of inhibiting immune serum (IS) (anti-rhIDU antibody titer 752 OD U/mL) (B),
or in the presence of partially inhibiting immune serum (PIS) (titer 450 OD U/mL) (C), with and without mannose 6-phosphate (M6P) or an Fc receptor blocking agent
(FcR block). For all panels, uptake into human fibroblasts is shown as filled bars and uptake into murine macrophages is shown as open bars. (A–C) were run together as a
single experiment (replicated five times). Error bars represent SD. *p < 0.05 versus human fibroblasts. (D) Intracellular rhIDU uptake into murine macrophages in the presence
of no serum (RhIDU), nonimmune serum (Ser), PIS, or purified rabbit anti-rhIDU IgG antibodies (IgG) with or without M6P. IDU activity is expressed as a percent of uptake into
murine macrophages in the absence of any factors. Error bars represent SD. *p < 0.05 versus rhIDU alone.

murine macrophages. The altered tissue distribution of rhIDU caused
by anti-rhIDU antibodies appeared to be partly due to reduced uptake
into ﬁbroblasts and partly due to enhanced uptake into tissue macrophages. These results imply that functional immune assays of rhIDU
uptake in vitro into ﬁbroblasts may not completely predict the impact
of the humoral immune response against enzyme replacement
therapy.
Delivery of recombinant proteins to treat diseases caused by genetic
haploinsufﬁciency or a total lack of a functional protein has proven
immensely valuable for treating patients, alleviating suffering and
prolonging and improving lifespan. However, the degree of amelioration of symptoms may be limited by a humoral immune response
against recombinant proteins that can alter tissue distribution of protein. Why and how this occurs is poorly understood. Designing strategies to alleviate or circumvent the immune response may improve
the effectiveness of protein therapeutics for the beneﬁt of patients.

Such novel inventions will ﬁrst require deeper insight into underlying
mechanisms.
Our results here show that even a low-level humoral immune
response against rhIDU that only partially inhibits rhIDU uptake
into ﬁbroblasts in vitro nevertheless may signiﬁcantly alter its
tissue distribution in vivo. In the liver, we found reduced rhIDU
distribution to hepatocytes in antibody-positive mice, but distribution to tissue macrophages was maintained. Antibodies also
reduced uptake of rhIDU into human ﬁbroblasts, but increased
uptake of rhIDU into murine macrophages. Our results also
corroborate and extend our previous study in dogs with MPS I
that reported that a high-titer humoral immune response against
rhIDU altered the tissue distribution of rhIDU preferentially
toward organs and tissues with high reticuloendothelial cell content and greatly diminished uptake into human ﬁbroblasts.5
Others have found similar altered biodistribution of rhIDU in
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immunized rats, with high antibody titers causing enhanced uptake into the liver as well as subcellular distribution into the endosomal compartment.9
In the present study using MPS I mice, we found similar alterations
in the tissue distribution of rhIDU, but our in vitro studies
comparing the uptake of rhIDU into ﬁbroblasts and macrophages
showed surprising results. In the absence of immune serum, the uptake of rhIDU into macrophages was less than the uptake of rhIDU
into human ﬁbroblasts when normalized to cell number. However,
when anti-rhIDU antibodies were present, the uptake of rhIDU into
macrophages was greater even than the uptake of rhIDU into human ﬁbroblasts when no antibodies were present. Collectively
then, our results and our previous studies5 indicate that anti-rhIDU
antibodies may alter tissue distribution both by suppressing ﬁbroblast uptake and by enhancing tissue macrophage uptake. These results suggest that new strategies to enhance effectiveness of rhIDU
might focus on methods that will both improve ﬁbroblast uptake
and reduce macrophage uptake of rhIDU. Furthermore, designing
in vitro assays that test ﬁbroblast and macrophage uptake of rhIDU
(and perhaps other recombinant proteins) could constitute a relatively rapid screening method, as opposed to relying on empiric
testing in vivo. Our results also suggest that in vitro assays to assess
the likely clinical impact of anti-rhIDU antibodies should not solely
focus on the inhibition of uptake into ﬁbroblasts, and underscore
the need to develop new strategies to limit humoral responses to
enzyme replacement therapy that signiﬁcantly limits the effectiveness of such therapies in MPS I and probably other lysosomal storage diseases as well.
The extent to which our results can be generalized to other diseases
that are treated by replacement of missing proteins with recombinant
proteins remains to be determined, but clearly our results are relevant
to at least some such therapeutic situations besides MPS I. For
example, Fabry disease, which is caused by deﬁciency of the lysosomal
enzyme alpha-galactosidase A, is treated by intravenous delivery of
recombinant enzyme. But the therapeutic response varies considerably, and one contributor to that variability is the presence and levels
of anti-galactosidase A antibodies that neutralize enzymatic activity
and can be associated with higher tissue and urinary levels of globotriaosylceramide substrate.10 Similarly, individuals with forms of
Pompe disease (caused by a genetic deﬁciency of acid alpha-glucosidase) that produce no alpha-glucosidase at all are at particularly high
risk of developing adverse immune responses associated with poorer
outcomes.11
In contrast, delivery of recombinant human acid alpha-glucosidase
to patients with forms of Pompe disease in which minimal or
modest amounts of enzyme are produced also induces early production of high titers of antibodies against that protein, but
titers decrease over time and do not typically affect uptake or activity of the recombinant enzyme. This seems to be due to a regulatory
T cell-mediated immunosuppression.12 That interpretation was also
supported by a report that anti-CD3 antibodies reduced anti-human
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alpha-glucosidase antibody titers in mice and prevented hypersensitivity reactions, and these effects were accompanied by reduced
numbers of both CD4+ and CD8+ T cells and an increased ratio
of regulatory T cells (i.e., CD4+ CD25+ FoxP3+) to CD4+
T cells.13 In addition, antibodies against glucocerebrosidase are
not usually a problem in enzyme replacement therapy for type 1
Gaucher disease, in part because these patients are not null for glucocerebrosidase and in part because macrophages are the target of
therapy.14
Furthermore, mechanisms by which antibodies might interfere with
efﬁcacy of recombinant proteins differ. For some therapeutic enzymes, the immune response hinders efﬁcacy by abolishing enzymatic
activity, whereas in other cases, the mechanism is inhibition of uptake
and lysosomal targeting. Antibodies to rhIDU do not affect enzymatic
activity, unlike the immune response to recombinant human alphagalactosidase A for Fabry disease.15 Rather, anti-rhIDU antibodies
interfere with uptake via mannose 6-phosphate receptors.5 Clinically,
patients with anti-rhIDU antibodies show less reduction in urinary
glycosaminoglycan excretion following rhIDU treatment, implying
a possible impairment of biochemical efﬁcacy.3,16 Uptake inhibition
by anti-drug antibodies has been shown for other recombinant enzymes, such as recombinant alpha-galactose 6-sulfatase for Morquio
A, although there is no evidence that the antibodies impact clinical
outcomes in this disorder.17
Notwithstanding the complexities and variability in immunogenic
responses to administration of recombinant therapeutic proteins,18–20
our results provide important new insights that will prove useful in
designing new therapeutic strategies that maximize therapeutic effects of rhIDU in MPS I. Furthermore, our results might guide the
design of therapies against other genetic diseases, in which delivery
of recombinant proteins is effective, for example, the six lysosomal
storage disorders, in which US Food and Drug Administration
(FDA)-approved recombinant enzyme replacement therapy is available and used clinically.18

MATERIALS AND METHODS
Study Animals and Enzyme Replacement Therapy

Animal experiments were approved by the Institutional Animal Care
and Use Committee at the Los Angeles Biomedical Research Institute
at Harbor-UCLA Medical Center, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care
(AAALAC).
The MPS I knockout mouse (B6.129-Iduatm1Clk/J) was acquired from
Jackson Laboratory (Bar Harbor, ME) and maintained on an inbred
background (C57BL/6).21 Heterozygous males and females were
used to generate mutant (Idua/) and wild-type (Idua+/+) mice
with mixed gender for this study. Genotype was determined
with primers: oIMR1451: 50 -GGAACTTTGAGACTTGGAATGAA
CCAG-30 ; oIMR1452: 50 -CATTGTAAATAGGGGTATCCTTGA
ACTC-30 ; and oIMR1453: 50 -GGATTGGGAAGACAATAGCAGG
CATGCT-30 . In order to avoid the interference of infrared signals

Molecular Therapy: Methods & Clinical Development Vol. 8 March 2018

www.moleculartherapy.org

caused by chlorophyll-degraded products, animals received a special
chlorophyll-free diet AIN-76A (Research Diet, New Brunswick, NJ)
and water ad libitum and were housed in constant temperature/
humidity, with a 12 hr light:12 hr dark cycle.
MPS I mice (n = 13) were sensitized to the enzyme by a weekly intravenous dose of 1.57 mg/kg body weight rhIDU (formulated as laronidase, lot #V011004 and V011005, 0.58 mg/mL in 150 mM NaCl,
100 mM sodium phosphate, 0.001% polysorbate 80, pH 5.8,
BioMarin Pharmaceutical, Novato, CA) from 4 weeks to 15 weeks
of age via tail vein injection. This dose was selected based on previous
studies in dogs.22 Three mice with an anti-rhIDU IgG antibody titer
greater than 15 OD U/mL died prior to the completion of the experiment, apparently from infusion reactions. Speciﬁcally, one mouse
was found dead 3 days after the 12th week of infusion. Two mice
died from anaphylaxis that occurred immediately following infusions
at week 12 (n = 1) and week 14 (n = 1). Anaphylaxis manifested as
labored breathing and lack of response to stimulus and tail pinch.
We began subsequent infusions with injections of diphenhydramine
(5 mg/kg body weight) 30 min prior to the procedure via intraperitoneal injection to prevent the anaphylaxis reactions. At 16 weeks of
age, MPS I mice previously sensitized to rhIDU (n = 10) and naive
to rhIDU (n = 6) were administrated one dose of 1.57 mg/kg body
weight of Alexa Fluor 680 labeled rhIDU (AF680-rhIDU; degree of
labeling 1.3 mol label/mol protein), which was previously showed
to retain its biochemical properties (including enzymatic activity,
cellular uptake, and lysosomal delivery).8
Sample Collections and Fluorescent Imaging

Blood samples were collected through the facial submandibular vein
every 4 weeks beginning at week 4. In vivo ﬂuorescence intensity was
measured in un-injected control mice (n = 2) and naive MPS I (n = 6)
mice at 0, 15, and 30 min and 1, 2, and 24 hr after the AF680-rhIDU
injection (at week 16) using the Maestro EX in vivo ﬂuorescence imaging system (Cambridge Research & Instrumentation [Cri], now
PerkinElmer [Caliper Life Sciences], Waltham, MA), with red excitation and emission ﬁlters for wavelengths at a range of 720–850 nm for
2,000 ms exposure. Average ﬂuorescence intensity was calculated using Maestro software (version 3.012).
24 hr after the injection of AF680-rhIDU, mice were sacriﬁced by CO2
asphyxiation and terminal blood samples were collected by cardiac
exsanguination. For biochemical evaluation, a portion of the organs
(hearts, lungs, spleens, kidneys, and livers) were rapidly frozen in
dry ice and stored at 80 C before homogenization. The rest of the
organs were imaged by Maestro EX imaging system to quantify the
distribution of AF680-rhIDU labeled enzyme and their ﬂuorescence
intensity before ﬁxation in 10% buffered formalin and further processed for parafﬁn embedding and histology.

X-100). Iduronidase activity was assessed using 250 mmol/L 4-methylumbelliferyl a-L-iduronide substrate (4-MUI) (Glycosynth, Warrington, Cheshire, UK), as previously described, but with a modiﬁed
incubation temperature (37 C) and incubation time (30 min).23 Net
ﬂuorescence was determined by RF-1501 spectroﬂuorophotometer
(Shimadzu, Columbia, MD) at the wavelength of 365 nm and
440 nm for excitation and emission, respectively. One activity unit is
deﬁned as the activity catalyzing the hydrolysis of 1 nmol substrate
in 1 hr at 37 C. Protein concentrations in the extracts were determined
by the Bradford method (Bio-Rad, Irvine, CA). Results were expressed
as U/mg of protein. GAG amount in tissue was assessed using the
carbazole reaction with glucuronic acid as the standard.24 Tissue results were expressed as nmol GAG (glucuronic acid) per mg protein.
Immunohistochemistry

Immunohistochemistry was performed with the EXPOSE IHC detection kit (Abcam, Cambridge, MA) on 10-mm-thick organ sections
with antibody against rhIDU (BP13, kindly donated by BioMarin
Pharmaceutical) and LAMP1 (ab24170, Abcam, Cambridge, MA)
following the manufacturer’s instructions. Slides were counterstained
with hematoxylin for light microscopic evaluation.
Cellular Uptake of rhIDU in MPS I Fibroblasts and Macrophages

MPS I mouse macrophages were derived from bone marrow monocytes following the protocol of Zhang et al.,25 with minor modiﬁcations. In brief, bone marrow monocytes were collected from the
femurs and cultured in the medium containing 10 ng/mL macrophage colony-stimulating factor (M-CSF) (PeproTech, Rocky
Hill, NJ) for 7 days. After eliminating non-adherent cells, adherent
macrophages were harvested for subsequent assays.
Freshly cultured bone-marrow-derived macrophages from MPS I
mouse and human skin ﬁbroblasts from an individual with MPS I
Hurler (GM 1391; Coriell Institute for Medical Research,
Camden, NJ) were seeded in 12-well cell culture plates at the concentration of 300,000 cells/wells. RhIDU was diluted to 18 U/mL in MEM
plus 1% L-glutamine. Rabbit anti-rhIDU IgG was obtained from two
different immunized rabbits by puriﬁcation of serum on a protein
A column (Thermo Fisher Scientiﬁc, Waltham, MA). Pre-immune
rabbit serum, immune serum, or puriﬁed anti-rhIDU IgG were added
at 1:1,000 dilution and preincubated for 1 hr at 37 C with diluted
rhIDU at the presence or absence of 5 mM mannose 6-phosphate
(Sigma-Aldrich, St. Louis, MO) or 0.5 mg/mL murine Fc receptor
blocking agent (eBioscience, San Diego, CA). The diluted serumrhIDU mixture (0.5 mL) with or without inhibitor(s) was added to
human MPS I ﬁbroblasts or murine MPS I bone-marrow-derived
macrophages and incubated for 1 hr at 37 C and 5% CO2. After
1 hr, cells were harvested and counted before they were lysed in
60 mL of PAD. Intracellular iduronidase activity was measured as
described above and results were expressed as U/million cells.

Biochemical Evaluations

For biochemical assays, organs were weighed (wet weight) and homogenized in 3 volumes of PAD buffer (10 mM sodium phosphate,
pH 5.8, 0.02% sodium azide, 0.1 mM dithiothreitol, and 0.1% Triton

Measurement of rhIDU-Specific IgG

Speciﬁc IgG antibodies against rhIDU were measured by ELISA. Brieﬂy,
96-well plates (Corning, Corning, NY) were coated overnight with
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0.2 mg rhIDU in acidic sodium phosphate buffer (pH 5.8). Following
blocking with 3% BSA in acidic phosphate-buffered saline (pH 5.8), serial dilutions of serum were added in triplicate to rhIDU-coated plates
and incubated at 37 C for 1 hr. The plates were washed, and alkalinephosphatase-conjugated goat anti-mouse IgG secondary antibody
(Southern Biotechnology Associates, Birmingham, AL) was added
and allowed to incubate for 1 hr at 37 C. Following a ﬁnal wash,
1 mg/mL p-nitrophenol phosphate substrate (Sigma-Aldrich, St. Louis,
MO) was added and allowed to develop at room temperature. The reaction was stopped after 1 hr by the addition equal volume of 0.1 M EDTA,
and absorbance values were read at 405 nm as OD units using a Synergy
2 spectrophotometer (BioTek, Winooski, VT). The calculated OD value
for any sample was taken from dilutions within the linear signal range.
Determination of Uptake Inhibition of rhIDU in Mouse Serum
Samples

MPS I human skin ﬁbroblasts GM 1391 were seeded in 12-well cell
culture cluster plates for a concentration of 300,000 cells/wells. Serum
samples collected at week 12 of the mice in the study was added at
1:1,000 dilution and preincubated for 1 hr at 37 C with 18 U/mL
rhIDU. The serum-rhIDU mixture (0.5 mL) was then added to
MPS I ﬁbroblasts and incubated for 1 hr at 37 C and 5% CO2. Cells
were lysed in 60 mL of PAD buffer and centrifuged. Intracellular iduronidase activity was measured with 15 mL cell lysate in triplicate as
described above, and results were normalized to pooled serum-rhIDU
samples from non-immunized controls and expressed as a percentage
toward the control sample.
Statistics

We performed statistical analyses using SYSTAT13 (Systat, Chicago,
IL). We used two-sample, two-tailed t tests, without adjustment for
multiple comparisons, or ANOVA with post hoc pairwise comparisons, as speciﬁed in the results. Where noted, we adjusted p values using the Bonferroni method to correct for multiple comparisons.
Linear regression analyses were performed using SYSTAT13 by the
least-squares method.
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